

**Amendments to the Claims:** This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims:**

1. - 24. (Canceled)

25. **(Currently Amended)** An isolated recombinant polypeptide comprising:  
(a) — the amino acid sequence SEQ ID NO:2[[:] or,  
(b) — an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a composition, which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

26. (Canceled)

27. **(Canceled)**

28. (Canceled)

29. **(Currently Amended)** The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises An isolated recombinant polypeptide comprising an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include coupled to a suitable carrier coupled to the polypeptide or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

30. (Canceled)

31. **(Currently Amended)** The isolated recombinant polypeptide of claim 25 29, wherein the immunogenic fragment of (b) comprises 20 or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include coupled to a suitable carrier coupled to the polypeptide or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33-34. (Canceled)

35. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 25.

36. - 39. (Canceled)

40. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented) The immunogenic composition of claim 40, wherein the immunogenic composition further comprises at least one other *Neisseria meningitidis* antigen other than a polypeptide comprising SEQ ID NO:2.

42. (Canceled)

43. (Previously Presented) A method for inducing an antibody in a mammal comprising administering the isolated recombinant polypeptide of claim 25 to the mammal in an amount effective to induce an antibody.

44. - 47. (Canceled)

48. (**Canceled**)

49. (**Canceled**)

50. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 29.

51. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29 and a pharmaceutically acceptable carrier.

52. - 56. (Canceled)

57. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 31.

58. (Canceled)

59. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31 and a pharmaceutically acceptable carrier.

60. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 35 and a pharmaceutically acceptable carrier.

61. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 48 and a pharmaceutically acceptable carrier.

62. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 50 and a pharmaceutically acceptable carrier.

63. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 57 and a pharmaceutically acceptable carrier.

64. (**New**) The immunogenic composition of claim 40, further comprising an adjuvant.

65. (**New**) The immunogenic composition of claim 51, further comprising an adjuvant.

66. (**New**) The immunogenic composition of claim 59, further comprising an adjuvant.

67. (**New**) The immunogenic composition of claim 60, further comprising an adjuvant.

68. (**New**) The immunogenic composition of claim 61, further comprising an adjuvant.

69. (**New**) The immunogenic composition of claim 62, further comprising an adjuvant.

70. (**New**) The immunogenic composition of claim 63, further comprising an adjuvant.

71. (**New**) The isolated recombinant polypeptide of claim 29, wherein the polypeptide is coupled to a carrier.

72. (**New**) The isolated recombinant polypeptide of claim 31, wherein the polypeptide is coupled to a carrier.